Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRAP1 | Q12931 | 11/20 | 0.38 |
| ▸ | HSP90B1 | P14625 | 6/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 7/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.36 |
| ▸ | SPR | P35270 | 1/20 | 0.35 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31281890 | 0.96 | TRAP1 (0.36) | TRAP1HSP90B1HSP90AA1HSP90AB1SPR | |
| SCHEMBL30377318 | 0.95 | TRAP1 (0.36) | TRAP1HSP90B1HSP90AA1HSP90AB1SPR | |
| SCHEMBL25210256 | 0.95 | TRAP1 (0.36) | TRAP1HSP90B1HSP90AA1HSP90AB1SPR | |
| SCHEMBL31281889 | 0.88 | TRAP1 (0.46) | TRAP1HSP90B1HSP90AA1HSP90AB1SPR | |
| SCHEMBL31281933 | 0.87 | SPR (0.35) | SPR | |
| SCHEMBL31282001 | 0.87 | TRAP1 (0.36) | TRAP1HSP90B1HSP90AA1HSP90AB1SPR | |
| SCHEMBL25221414 | 0.85 | TRAP1 (0.43) | TRAP1HSP90B1HSP90AA1HSP90AB1SPR | |
| SCHEMBL30377827 | 0.85 | TRAP1 (0.43) | TRAP1HSP90B1HSP90AA1HSP90AB1SPR | |
| SCHEMBL25211589 | 0.85 | TRAP1 (0.39) | TRAP1HSP90B1HSP90AA1HSP90AB1SPR | |
| SCHEMBL31282109 | 0.85 | TRAP1 (0.38) | TRAP1HSP90B1HSP90AA1HSP90AB1SPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425453-A1 | ISOINDOLINES AS PMS2 INHIBITORS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2024-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425453-A1 | ISOINDOLINES AS PMS2 INHIBITORS | PMS2, MSH2, RECQL | TRAP1 1557/4885HSP90B1 2082/4885HSP90AA1 2367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.